Soligenix Inc. (NASDAQ:SNGX) received a $4.00 target price from Maxim Group in a note issued to investors on Thursday, May 11th. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price target suggests a potential upside of 98.02% from the company’s current price.
Soligenix (NASDAQ SNGX) opened at 2.02 on Thursday. The stock has a 50 day moving average price of $2.49 and a 200 day moving average price of $2.60. The stock’s market cap is $11.46 million. Soligenix has a 52 week low of $2.02 and a 52 week high of $14.40.
Soligenix (NASDAQ:SNGX) last posted its earnings results on Thursday, May 11th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by $0.02. Soligenix had a negative net margin of 41.74% and a negative return on equity of 102.83%. The company had revenue of $1.30 million during the quarter. On average, equities analysts predict that Soligenix will post ($0.63) earnings per share for the current year.
WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/06/17/soligenix-inc-sngx-given-a-4-00-price-target-at-maxim-group-updated-updated-updated.html.
In other news, major shareholder Randal J. Kirk sold 160,968 shares of the stock in a transaction dated Monday, May 8th. The stock was sold at an average price of $3.12, for a total value of $502,220.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.09% of the stock is currently owned by company insiders.
Soligenix Company Profile
Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
What are top analysts saying about Soligenix Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Soligenix Inc. and related companies.